“Those that are trying to lose weight may want a higher protein intake to help with muscle retention,” he said. Physical activity also plays a huge role: If you’re lifting weights, that presents a need to increase your protein intake—same…
Blog
-
Motorola’s Razr Ultra and the Marshall Emberton II top this week’s best deals
If you’ve been thinking about buying a foldable phone that truly stands out, few models can rival the 2025 Motorola Razr Ultra, which is currently on sale at Amazon and Best Buy with 16GB of RAM and 512GB starting at $999.99 ($300 off), its…
Continue Reading
-
It’s Qwen’s world and we get to live in it, on CAISI’s report, & GPT-OSS update
Before getting into the latest artifacts, there are a couple of pieces of crucial open ecosystem we have to cover.
First, the Center for AI Standards and Innovation (CAISI) released a report that observed the ecosystem and evaluated DeepSeek 3.1…
Continue Reading
-
Stem Cell Textbooks Challenged by “Immortal” Flatworm – SciTechDaily
- Stem Cell Textbooks Challenged by “Immortal” Flatworm SciTechDaily
- Flatworm Stem Cells Regenerate Through Contactless Communication the-scientist.com
- This Tiny Worm May Be the Key to Human Limb Regeneration VICE
- Flatworms defy stem cell…
Continue Reading
-
Listening For Gravitational Waves In The Rhythm of Pulsars
At the dawn of time, so the theory goes, the cosmos underwent a flash of rapid expansion. Almost instantly the visible Universe grew from a volume smaller than a proton to a spherical region nearly two meters across. It’s a moment known…
Continue Reading
-
Evaluating Valuation After FDA Breakthrough Therapy Designation for BPL-003
Atai Life Sciences (NasdaqGM:ATAI) and its partner Beckley Psytech just received Breakthrough Therapy designation from the FDA for BPL-003, their investigational nasal spray for treatment-resistant depression. This recognition accelerates the path to potential approval and highlights excitement about new mental health therapies.
See our latest analysis for Atai Life Sciences.
Atai’s FDA breakthrough news supercharged momentum that was already building. The share price has spiked 303% year-to-date, and the 1-year total shareholder return is an eye-popping 404%. With fresh capital raised through a $130 million equity offering and continued sector-wide interest in psychedelic medicines, investors are clearly betting on both near-term catalysts and the company’s longer-term potential.
If regulatory milestones like this have you curious about other breakthrough opportunities, this is a great time to explore the latest See the full list for free..
With Atai’s massive rally, strong analyst buy ratings, and a price target well above current levels, investors are now asking whether the stock remains undervalued or if recent gains have already priced in the next stage of growth.
Atai Life Sciences trades at a price-to-book ratio of 9.6x, placing it well above the typical level in the pharmaceutical industry and raising questions about how much growth is being priced in at $6.45 per share.
The price-to-book ratio compares a company’s market value to its book value, providing a sense of how much investors are willing to pay for each dollar of assets. In pharmaceuticals, where early-stage R&D companies are often years from profitability, elevated price-to-book multiples can reflect either strong future expectations or indicate market exuberance.
While Atai’s ratio trails the peer group average of 11.3x, it remains much higher than the broader US Pharmaceuticals industry average of 2.4x. This suggests investors have high expectations, but maintaining this premium may be challenging without substantial revenue growth or positive earnings developments to support this year’s performance.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-Book of 9.6x (OVERVALUED)
However, weak profitability and the potential for slower revenue growth could quickly cool investor enthusiasm if expectations get ahead of fundamentals.
Find out about the key risks to this Atai Life Sciences narrative.
If you have your own perspective or want to dive deeper, you can examine the numbers and construct your own take in just a few minutes, or Do it your way.
Continue Reading
-
Comet C/2025 R2 SWAN with messier 16 and Messier 17 – 17 Oct. 2025.
The beautiful comet C/2025 R2 SWAN is putting a wonderful show out there, thanks to the deep-sky friends it is meeting.
Comet C/2025 R2 SWAN with Messier 16 and Messier 17. 17 Oct. 2025.
The image above comes from the average of five,…
Continue Reading
-
Looking at the Narrative for Spotify as Analyst Sentiment and Growth Drivers Shift
Spotify Technology’s consensus analyst price target has edged down slightly, from $747.78 to $746.42. This signals a minor revision in how experts value the stock. This subtle shift comes as analysts weigh encouraging signs of revenue growth and new product initiatives, while also considering ongoing concerns around risk and market expectations. Read on to see how you can keep track of these evolving perspectives and stay informed on Spotify’s investment outlook.
Analysts have issued a variety of recent notes on Spotify Technology, reflecting both optimism and caution regarding the company’s near- and medium-term prospects. Their commentary provides insights into the factors driving updates to price targets, ratings, and overall investor sentiment.
🐂 Bullish Takeaways
-
Several firms, including JPMorgan, Guggenheim, Canaccord, and BNP Paribas Exane, have expressed a constructive outlook, highlighting robust subscriber and user growth, improving engagement and conversion, and ongoing international price increases.
-
JPMorgan raised its price target on Spotify to $805 from $740, citing updates to its model for international price hikes and projecting 14% year-over-year revenue growth through 2026. The firm also flagged potential upside if a U.S. price increase is implemented.
-
Guggenheim lifted its price target to $850 from $800 as it expects further price increases, particularly in large markets, to fuel upward revisions to revenue and profits.
-
Canaccord continues to view near-term share pullbacks as buying opportunities, basing its bullish stance on improving engagement, steady subscriber growth, pricing power, and a renewed focus on the ads business. The firm maintains a Buy rating with an $850 price target.
-
BNP Paribas Exane initiated coverage with an Outperform rating and a $900 price target, marking one of the highest targets among peers.
-
Other firms such as Wells Fargo and KeyBanc maintain Overweight ratings, indicating ongoing belief in Spotify’s pricing power and margin expansion potential, despite recent stock volatility.
-
Key drivers rewarded by analysts include execution on product momentum, strategic price increases, differentiation versus peers, and transparent communication of growth targets.
🐻 Bearish Takeaways
-
Caution has emerged among firms such as Goldman Sachs and Citi, who either downgraded their ratings or highlighted risks in their research.
-
Goldman Sachs downgraded Spotify to Neutral from Buy, even as it modestly raised its price target to $770 from $765. The firm sees a balanced risk/reward profile, suggesting much of Spotify’s forward growth may already be priced into the shares, particularly ahead of the Q3 earnings report. Goldman nonetheless expects solid mid-teens annual revenue growth over the next four years.
-
Citi increased its price target to $750 from $715 but maintained a Neutral rating, citing concerns that consensus estimates may underestimate the growing wholesale cost of music.
-
Phillip Securities upgraded the stock to Neutral from Reduce, but noted that near-term expectations are being tempered by increased investments and operating costs.
-
Analysts in this group tend to cite concerns over valuation, the extent to which future upside is already reflected in the share price, rising costs, and the impact of recent investment cycles as factors warranting a more cautious outlook.
Continue Reading
-
-
Pakistan vaccinates girls against HPV, cervical cancers
Pakistan vaccinates girls against HPV, cervical cancers | The Jerusalem Post Continue Reading
-
China’s fingernail-sized chip can map 5,600 stars in seconds
Imagine a device no bigger than a fingernail that can see the world, and the stars, in colours so precise that it leaves traditional cameras and spectroscopes far behind. That’s exactly what a team of Chinese researchers has created at…
Continue Reading